NCT07020130

Brief Summary

A prospective observational study included all patients undergoing percutaneous coronary intervention(PCI) in Fujian Provincial Hospital from January 1st 2012 to December 31st 2018. The aim was to determine the incidence,risk factors,prophylactic strategy and outcomes of CI-AKI in patients undergoing PCI.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
3,030

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2012

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2012

Completed
6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2018

Completed
12 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2018

Completed
6.4 years until next milestone

First Submitted

Initial submission to the registry

May 26, 2025

Completed
18 days until next milestone

First Posted

Study publicly available on registry

June 13, 2025

Completed
Last Updated

June 13, 2025

Status Verified

June 1, 2025

Enrollment Period

6 years

First QC Date

May 26, 2025

Last Update Submit

June 5, 2025

Conditions

CIN

Outcome Measures

Primary Outcomes (2)

  • CI-AKI

    This was due to acute kidney injury following the use of intravascular contrast media. Serum creatinine is the primary measuring modalities.

    5 year

  • CKD

    Chronic renal structural and functional disorders that occurred during follow-up after administration of intravascular contrast agents, estimated glomerular filtration rate (eGFR) as the primary measuring modalities.

    5 year

Secondary Outcomes (1)

  • all-cause mortality

    5 year

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All Critically ill patients undergoing PCI at ICU were enrolled

You may qualify if:

  • Critically ill patients undergoing PCI at ICU

You may not qualify if:

  • pregnancy lactation end-stage renal disease (eGFR \<15 mL/min/1.73 m2) long-term dialysis treatment intravascular administration of contrast medium within the last 7 or 3 days postoperatively

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Unknown Facility

Fuzhou, Fujian, China, China

Location

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Director

Study Record Dates

First Submitted

May 26, 2025

First Posted

June 13, 2025

Study Start

January 1, 2012

Primary Completion

January 1, 2018

Study Completion

December 31, 2018

Last Updated

June 13, 2025

Record last verified: 2025-06

Locations

CN(1)